Boston Scientific (BSX) Jumps 9% After Q1 2026 Earnings Release

NYSE: BSX · April 22, 2026 · 3 min read

Boston Scientific Corporation (NYSE: BSX) advanced $5.35, or 8.99%, to $64.87 on Wednesday after the company filed an official results-of-operations 8-K with the SEC on April 22, 2026 — a disclosure confirming the release of its most recent quarterly earnings. The move placed BSX among the session's most active and notable gainers in the S&P 500, a day when the broader index itself hit record highs on the back of upbeat corporate results.

Q1 2026 Financial Snapshot

• Market capitalisation: $96.4B following today's advance
• Trailing P/E: 33.4x | Forward P/E: 16.7x — a meaningful compression that implies the market expects strong near-term earnings growth
• Revenue growth (YoY): 15.9%
• Earnings growth (YoY): 18.5%
• Gross margin: 68.8%
• Operating margin: 19.7%
• Net margin: 14.4%
• 52-week range: $59.38 – $109.50; today's close sits just above the 52-week low

What Drove the Move

The fundamentals on record tell a consistent story of durable top- and bottom-line momentum. Revenue expanding at nearly 16% year-over-year alongside earnings growth of 18.5% signals that (NYSE: BSX) is scaling profitably — gross margins of 68.8% reflect the pricing power typical of a diversified medical-device leader, while an operating margin of 19.7% points to disciplined cost management.

The wide gap between the trailing P/E of 33.4x and the forward P/E of 16.7x is notable. It suggests Wall Street analysts are modelling a near-doubling of earnings power on a per-share basis, which, if borne out, would substantially re-rate the stock's valuation profile. Today's broader market backdrop — with both the Nasdaq Composite and S&P 500 registering record closes amid strong earnings season results — amplified investor receptivity to the release.

Wall Street View

Analyst sentiment toward (NYSE: BSX) is firmly constructive. As of the April 2026 consensus, 13 analysts rate the stock Strong Buy and 25 rate it Buy, against just 3 Holds and zero Sell-side negatives — a total of 38 Buy-or-better ratings out of 41 covering analysts. Compared with the March 2026 period, the Buy camp gained two seats while Strong Buys edged down by one, suggesting a modest rotation within the bullish tier rather than any erosion of conviction. No price targets were available in the current data set.

Investor Takeaway

With an SEC-confirmed earnings filing, a near-9% single-session gain, and one of the most lopsided bullish analyst line-ups in the S&P 500 Health Care sector, (NYSE: BSX) is clearly drawing attention this earnings cycle. The combination of double-digit revenue and earnings growth with margins that remain well above sector medians underpins the buy-side enthusiasm reflected in analyst ratings. Investors should note that the stock is currently trading near the lower end of its $59.38 – $109.50 52-week range, a context worth monitoring as the full earnings details are digested.